Clinical characteristics and outcomes of extrauterine epithelioid trophoblastic tumors
- 44 Downloads
Epithelioid trophoblastic tumor (ETT) derived from intermediate trophoblasts is one type of gestational trophoblastic neoplasia (GTN), and it accounts for less than 2% of all gestational trophoblastic diseases (GTD). Extrauterine ETT is extremely rare, and there is currently no consistent strategy for its treatment and management. Therefore, the aim of the study is to analyze and summarize the clinicopathologic features of extrauterine ETT with or without metastasis.
The Web of Knowledge, Google Scholar, EMbase, congress of library, and PubMed were searched for extrauterine ETT without primary uterine lesions. All available data were extracted from published case reports or serial case reports, and then, the clinical and pathological characteristics were analyzed.
Twenty-two clinical studies consisting of 27 patients diagnosed with extrauterine ETT, according to the given inclusion and exclusion criteria, were included in the study. A total of 27 cases of extrauterine ETT were identified. Of these cases, four (14.81%) were located in the lungs, three (11.11%) in the ovaries, two (7.41%) in the vagina, and eight (29.63%) patients had other primary lesions. The patients originated from different continents, with 59% located in Asia and 26% in North America. Among 23 patients, the antecedent pregnancy prior to the diagnosis was full-term in 12 cases, abortion in 6 cases, hydatidiform mole in 3 cases, and invasive mole in 1 case. From the available antecedent information on pregnancy, the median interval from pregnancy to diagnosis of extrauterine ETT was 4 years. Additionally, the median gravidity and para of the patients was three times and two times, respectively. The median hCG titer was 14,374 mIU/mL in 5 patients, and the mean β-HCG titer was 3,724,805 mIU/mL in 14 patients. For all patients, the disease was confined to extrauterine ETT at diagnosis. From the available information, 20 cases were successfully treated by extraction of local lesions, and 12 cases received chemotherapy. Diagnosis was confirmed by histological tests. The Ki-67 staining ranged from 8.7 to 80%, and tumors were positive for hCG, PLAP, EMA, and p63.
In this study, we observed that abnormal levels of serum hCG titers and the local presentation of lesions with varying intervals after antecedent term pregnancy were the most common presenting features of extrauterine ETT. In addition, we found that the extraction of extrauterine lesions was needed for the treatment of extrauterine ETT. Of course, the follow-up was also important.
KeywordsGestational trophoblastic disease Epithelioid trophoblastic tumor Extrauterine lesion Immunohistochemistry Surgery Chemotherapy
TZ conceived the scientific idea, TZ, XZ and HX performed the analyses and prepared the manuscript, TZ contributed to the preparation of the manuscript, LX and LG provided clinical data and contributed to the discussion of the data, while RA and YX supervised the project. All authors read and approved the final manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
- 10.Frijstein MM, Lok CAR, Trommel NE, Kate-Booij MJT, Massuger L, Werkhoven E, Kaur B, Tidy JA, Sarwar N, Golfier F et al (2018) Management and prognostic factors of epithelioid trophoblastic tumors: results from the international society for the study of trophoblastic diseases database. Gynecol Oncol 152:361–367CrossRefGoogle Scholar
- 16.Ru Luo HS, Chen X, Lü B, Shao H (2016) Extrauterine epithelioid trophoblastic tumor of the vagina: a case report and literature review. Int J Clin Exp Med 9(11):22041–22047Google Scholar
- 18.Fenichel P, Rouzier C, Butori C, Chevallier P, Poullot AG, Thyss A, Mouroux J (2014) Extragestational beta HCG secretion due to an isolated lung epithelioid trophoblastic tumor: microsatellite genotyping of tumoral cells confirmed their placental origin and oriented specific chemotherapy. J Clin Endocr Metab 99(10):3515–3520CrossRefGoogle Scholar
- 29.Parker A, Lee V, Dalrymple C, Valmadre S, Russell P (2003) Epithelioid trophoblastic tumour: report of a case in the fallopian tube. Pathology 35(2):136–140Google Scholar
- 32.Zhang X, Shi H, Chen X (2014) Epithelioid trophoblastic tumor after induced abortion with previous broad choriocarcinoma: a case report and review of literature. Int J Clin Exp Pathol 7(11):8245–8250Google Scholar
- 34.Braga A, Uberti EM, Fajardo Mdo C, Viggiano M, Sun SY, Grillo BM, Padilha SL, de Andrade JM, de Souza CB, Madi JM et al (2014) Epidemiological report on the treatment of patients with gestational trophoblastic disease in 10 Brazilian referral centers: results after 12 years since International FIGO 2000 Consensus. J Reprod Med 59(5–6):241–247Google Scholar
- 36.Tempfer C, Horn LC, Ackermann S, Beckmann MW, Dittrich R, Einenkel J, Günthert A, Haase H, Kratzsch J, Kreissl MC et al (2016) Gestational and non-gestational trophoblastic disease. Guideline of the DGGG, OEGGG and SGGG (S2k level, AWMF registry no. 032/049, December 2015). Geburtshilfe Frauenheilkd 76(2):134–144CrossRefGoogle Scholar
- 38.Bolze PA, Attia J, Massardier J, Seckl MJ, Massuger L, van Trommel N, Niemann I, Hajri T, Schott AM, Golfier F (2015) Formalised consensus of the European organisation for treatment of trophoblastic diseases on management of gestational trophoblastic diseases. Eur J Cancer 51(13):1725–1731CrossRefGoogle Scholar
- 40.Stichelbout M, Devisme L, Franquet-Ansart H, Massardier J, Vinatier D, Renaud F, Kerdraon O (2016) SALL4 expression in gestational trophoblastic tumors: a useful tool to distinguish choriocarcinoma from placental site trophoblastic tumor and epithelioid trophoblastic tumor. Hum Pathol 54:121–126CrossRefGoogle Scholar
- 41.Li X, Feng F, Xiang Y, Wan X, Ren T, Yang J (2015) Value of laparoscopic surgery in the diagnosis of suspected gestational trophoblastic neoplasia cases with uterine mass. Zhonghua Fu Chan Ke Za Zhi 50(12):910–914Google Scholar
- 44.Worley MJ Jr, Elias KM, Horowitz NS, Quade BJ, Berkowitz RS (2018) Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: a case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute. Gynecol Oncol 148(1):5–11CrossRefGoogle Scholar